Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Sensitive Assessment of Acute Optic Neuritis by a New, Digital Flicker Test

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Can DMCO Detect Visual Field Loss in Neurological Patients? A Secondary Validation Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Aquaporin-1 Expression in Retinal Pigment Epithelial Cells Overlying Retinal Drusen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Functional-structural assessment of the optic pathways in patients with optic neuritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

BACKGROUND: The Aulhorn flicker test (AFT) previously showed promise in diagnosing acute optic neuritis (ON) albeit with suboptimal sensitivity. A new, digitalized version of the AFT (the DFT) has not previously been examined in acute ON.

OBJECTIVES: To examine the sensitivity, specificity and reproducibility of the DFT in acute ON.

METHOD: The DFT assesses the subjective brightness of a flickering field (1-60 Hz). In normal subjects, brightness enhancement occurs at intermediate frequencies, whereas in acute ON darkness enhancement (DE) is hypothesized. AFT and DFT measurements were obtained in acute ON patients (≤31 days from first symptom) with DE as a quantitative covariate. Reproducibility of the DFT end point was assessed in the form of an intraclass correlation.

RESULTS: 30 untreated first-time acute ON patients and 55 healthy controls were examined. AFT and DFT were performed 12.7 days (range: 4-30) following ON onset. The DFT showed a sensitivity of 0.93 (95% CI = 0.78-0.99) to a specificity of 0.96 (95% CI = 0.87-1.00). The AFT showed a sensitivity of 0.76 (95% CI = 0.56-0.90) to a specificity of 1.00 (95% CI = 0.93-1.00). No significant correlation was shown between DFT and visual acuity. The intraclass correlation of the DFT end point in healthy subjects was 0.84.

CONCLUSIONS: We present a new DFT in acute ON displaying a high specificity of 0.96 and a sensitivity of 0.93. Our study indicates the DFT to be an accurate and easy-to-use tool in diagnosing acute ON, which may be especially helpful in atypical cases.

OriginalsprogEngelsk
TidsskriftOphthalmic Research
Vol/bind63
Udgave nummer3
Sider (fra-til)332-340
Antal sider9
ISSN0030-3747
DOI
StatusUdgivet - 2020

Bibliografisk note

© 2019 S. Karger AG, Basel.

ID: 58956519